当前位置:首页 - 行情中心 - 贝瑞基因(000710) - 财务分析 - 利润表

贝瑞基因

(000710)

  

流通市值:29.06亿  总市值:33.73亿
流通股本:3.05亿   总股本:3.54亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入865,605,843.9560,696,060.91280,207,812.41,368,007,211.88
营业收入865,605,843.9560,696,060.91280,207,812.41,368,007,211.88
二、营业总成本911,575,255.95601,557,960.94282,899,819.61,417,944,547.37
营业成本474,032,155.32317,358,792.44147,324,541.77783,647,154.28
税金及附加5,917,602.323,326,148.91,528,155.918,616,446.9
销售费用230,379,289.55147,085,538.0972,804,724.42303,589,219.59
管理费用118,125,614.2478,854,604.8737,401,370.02197,824,060.15
研发费用72,322,144.9947,511,079.6820,680,673.9106,735,118.84
财务费用10,798,449.537,421,796.963,160,353.5817,532,547.61
其中:利息费用-8,129,258.563,605,013.4517,635,243.61
其中:利息收入-1,122,669.2-533,991.762,357,540.2
加:公允价值变动收益-20,835,871.91-13,580,225.64--84,887,086.93
加:投资收益-36,623,949.88-28,959,382.14-9,436,348.18-59,419,338.18
资产处置收益1,726---353,024.78
信用减值损失(新)-21,801,272-9,015,209.32-6,670,255.61-101,461,206.33
其他收益3,856,380.632,214,042.111,412,798.469,160,211.87
营业利润平衡项目0000
四、营业利润-121,372,399.21-90,202,675.02-17,385,812.53-286,897,779.84
加:营业外收入570,905.54680,737.99257,214.44,544,424.5
减:营业外支出1,409,384.611,241,484.56551,616.01904,890.08
利润总额平衡项目0000
五、利润总额-122,210,878.28-90,763,421.59-17,680,214.14-283,258,245.42
减:所得税费用10,921,710.593,020,505.822,430,230.32-31,008,393.82
六、净利润-133,132,588.87-93,783,927.41-20,110,444.46-252,249,851.6
持续经营净利润-133,132,588.87-93,783,927.41-20,110,444.46-252,249,851.6
归属于母公司股东的净利润-134,956,919.35-95,107,757.01-20,738,437.15-254,778,590.81
少数股东损益1,824,330.481,323,829.6627,992.692,528,739.21
(一)基本每股收益-0.38-0.27-0.06-0.82
(二)稀释每股收益-0.38-0.27-0.06-0.82
八、其他综合收益3,176,915.43,825,302.65-2,432,985.919,240,965.08
归属于母公司股东的其他综合收益2,268,541.782,751,158.99-1,844,698.7214,763,250.34
九、综合收益总额-129,955,673.47-89,958,624.76-22,543,430.36-233,008,886.52
归属于母公司股东的综合收益总额-132,688,377.57-92,356,598.02-22,583,135.87-240,015,340.47
归属于少数股东的综合收益总额2,732,704.12,397,973.2639,705.517,006,453.95
公告日期2023-10-282023-08-162023-04-292023-04-08
审计意见(境内)标准无保留意见
TOP↑